Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortization of Deferred ChargesCapital ExpendituresCapital ExpendituresCash from Financing ActivitiesCash from Financing ActivitiesCash from Investing ActivitiesCash from Investing ActivitiesCash from OperationsCash from OperationsChange in Account PayablesChange in Account PayablesChange in Accured ExpensesChange in Accured ExpensesChange in CashChange in ReceivablesChange in ReceivablesDepreciation & Amortization (CF)Depreciation & Amortization (CF)Free Cash FlowFree Cash FlowGains from Investment SecuritiesGains from Investment SecuritiesLong-Term Debt IssuancesNet Cash FlowNet Cash FlowNet IncomeShare-based CompensationShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Inhibrx Biosciences (INBX) Gains from Investment Securities (2023 - 2025)

Inhibrx Biosciences (INBX) has disclosed Gains from Investment Securities for 3 consecutive years, with $2000.0 as the latest value for Q4 2025.

  • Quarterly Gains from Investment Securities rose 100.06% to $2000.0 in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $2000.0 through Dec 2025, changed 0.0% year-over-year, with the annual reading at $2000.0 for FY2025, 0.0% changed from the prior year.
  • Gains from Investment Securities for Q4 2025 was $2000.0 at Inhibrx Biosciences, up from -$2000.0 in the prior quarter.
  • The five-year high for Gains from Investment Securities was $3.6 million in Q2 2024, with the low at -$3.5 million in Q4 2024.
  • Average Gains from Investment Securities over 3 years is $205000.0, with a median of $2000.0 recorded in 2023.
  • The sharpest move saw Gains from Investment Securities crashed 1750.0% in 2024, then soared 100.06% in 2025.
  • Over 3 years, Gains from Investment Securities stood at $1.6 million in 2023, then plummeted by 317.01% to -$3.5 million in 2024, then skyrocketed by 100.06% to $2000.0 in 2025.
  • According to Business Quant data, Gains from Investment Securities over the past three periods came in at $2000.0, -$2000.0, and $2000.0 for Q4 2025, Q3 2025, and Q2 2025 respectively.